Pharmacological treatment of type 2 diabetes.
Hermans
M P
MP
Service d'Endocrinologie et Nutrition Cliniques universitaires UCL Saint Luc UCL 54.74 Avenue Hippocrate 54 B-1200 Brussels, Belgium. michel.hermans@diab.ucl.ac.be
Buysschaert
M
M
D001645:Biguanides / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D045162:Thiazolidinediones / Q000627:therapeutic use*
D001645:Biguanides; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones